MediVas, Nautilus Biotech, Wyeth deal

WYE's Wyeth Pharmaceuticals unit and Nautilus partnered to discover novel recombinant Factor IX proteins to treat hemophilia B. Nautilus will make specific changes to the amino acid sequence to increase the duration of action of recombinant Factor IX compounds. WYE will develop, manufacture and commercialize resulting products. Nautilus received an undisclosed upfront payment and R&D funding and is eligible for milestones and royalties. ...